Acetazolamide Market
Acetazolamide is an enzyme inhibitor, which acts specifically on carbonic anhydrase. Acetazolamide, sold under the trade name Diamox, is used to treat glaucoma, altitude sickness, epilepsy, fluid retention, heart failure, and seizures.
In addition to this, acetazolamide (carbonic anhydrase inhibitor) is effective in controlling fluid secretions, to treat certain convulsive disorders, and promotes diuresis in instances of abnormal fluid retention such as cardiac edema.
Increasing effectiveness of acetazolamide in treating other indication such as drug induced edema and brain tumor glioblastoma is offering growth prospective for key drug manufacturers in this market. For instance, according to a new study published in Science Translational Medicine Journal in July 2018, acetazolamide may also be effective in treating glioblastoma, fast-growing brain tumor. As per the study findings, acetazolamide can restore temozolomide’s (TMZ) ability to kill tumor cells. Furthermore, the study suggested that the combination of acetazolamide with TMZ may be an effective subgroup to consider for trial for patients with high BCL-3 expression.
Market Dynamics
Increasing prevalence of glaucoma and its risk factors among global population is propelling demand for acetazolamide during the forecast period. Moreover, acetazolamide is commonly used for preventing high altitude illness, this increases the utility of the drug.
For instance, according to the International Journal of Advanced Medical and Health Research, 2015, glaucoma is seen to be the second major reason causing blindness among people across the world, followed by cataract.
Furthermore, according to the BrightFocus Foundation, June 2017 data findings, over 3 million Americans suffer from glaucoma, out of which 2.7 million (aged 40 and older) are affected by its most common form, open-angle glaucoma. Also, high prevalence of eye disorder in the geriatric population and nutritional deficiency in the younger population due to changing food habits are other factors affecting the health of the people globally, which might lead to boost growth of acetazolamide market. Acetazolamide capsule taken once a day by patients with chronic glaucoma offers a substantial pressure-lowering effect, which lasts at least 23 hours.
Acetazolamide helps in preventing acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone, which can mask symptoms and therefore carries greater risk.
Key features of the study
Market Segmentation
Table of Contents
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
